TY - JOUR T1 - A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular disease JF - medRxiv DO - 10.1101/2020.02.16.20023010 SP - 2020.02.16.20023010 AU - Genevieve M. Leyden AU - Tom R. Gaunt AU - Tom G. Richardson Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/20/2020.02.16.20023010.abstract N2 - Importance New drugs which provide benefit alongside statin mono-therapy are warranted to reduce risk of cardiovascular disease.Objective To systematically evaluate the genetically predicted effects of 8,851 genes and cardiovascular disease risk factors using data from the UK Biobank and subsequently prioritize their potential to reduce cardiovascular disease in addition to statin therapy.Design, Setting, and Participants A factorial Mendelian randomization study using individual level data from the UK Biobank study. This population-based cohort includes a total of 502,602 individuals aged between 40 and 96 years old at baseline who were recruited between 2006 to 2010.Exposures Genetic variants robustly associated with the expression of target genes in whole blood (based on P<5×10−08) were used to construct gene scores using findings from the eQTLGen consortium (n=31,684).Main Outcomes and Measures Genetically predicted effects for each of the 8,851 genes were firstly evaluated with 5 measured outcomes from the UK Biobank in turn (body mass index, diastolic blood pressure, systolic blood pressure, low-density lipoproteins and triglycerides). Effects surviving multiple comparisons from this initial analysis were subsequently analyzed using factorial Mendelian randomization to evaluate evidence of an additive beneficial effect on cardiovascular disease risk compared to a HMGCR genetic score acting as a proxy for statin inhibition. Finally, a phenome-wide analysis was undertaken to evaluate predicted effects between prioritized targets and 569 outcomes in the UK Biobank to highlight potential adverse side-effects.Results 377 genetically predicted effects on cardiovascular disease risk factors were identified by Mendelian randomization (based on P<1.13×10−6). Of the 68 druggable genes, 20 candidate genes were predicted to lower cardiovascular disease risk in combination with statin treatment (P<7.35×10−4). Genes such as FDFT1 were predicted to have added benefit with statin therapy (OR=0.93; 95% CI, 0.91-0.95; P=2.21×10−10) but are unlikely to make safe targets due to their predicted effects on adverse side effects. In contrast, PRKCE provided evidence of a putative added benefit in combination with statins (OR=0.94; CI, 0.91-0.96; P=1.72×10−9) with no predicted adverse effects.Conclusions and Relevance Through the application of a systematic factorial Mendelian randomization analysis, we have prioritized (and deprioritized) potential drug targets predicted to reduce cardiovascular disease risk in addition to statin therapy.Question Can naturally occurring genetic variation in a population help us highlight and prioritize novel therapeutic targets for the treatment of cardiovascular disease?Findings In this factorial Mendelian randomization study of 334,915 individuals, we found that a genetically predicted 0.09 mmol/L decrease in LDL cholesterol attributed to statin inhibition results in 4.1% lower risk of cardiovascular disease. We then highlighted various genetic targets which were genetically predicted to further reduce disease risk without evidence of adverse side effects, such as PRKCE which is involved in the development of cardiac hypertrophy and reduced risk of cardiovascular disease by 6.4% in addition to statin therapy.Meaning Evidence from genetic analyses can improve the likelihood of success for therapeutic targets and findings from this study have prioritized several promising candidates for the treatment of cardiovascular disease.Competing Interest StatementTRG receives research funding from GlaxoSmithKline and Biogen although neither company contributed to design or implementation of this study.Funding StatementThis work was supported by the Integrative Epidemiology Unit which receives funding from the UK Medical Research Council and the University of Bristol (MC_UU_00011/4). GML is supported by the British Heart Foundation (FS/17/60/33474). TGR is a UKRI Innovation Research Fellow (MR/S003886/1).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics used in this study are available from the eQTLGen consortium (https://www.eqtlgen.org/) and the MR-Base platform (http://www.mrbase.org/). All individual-level data analysed in this study can be accessed with an application to the UK Biobank study (https://www.ukbiobank.ac.uk/).CVDCardiovascular diseaseRCTRandomized control trialMRMendelian RandomizationGWASGenome wide association studyeQTLexpression quantitative lociUKBUK BiobankPheWASPhenome wide association studySNPSingle nucleotide polymorphismBMIBody mass indexDBPDiastolic blood pressureSBPSystolic blood pressureLDLLow-density lipoproteinsTGTriglyceridesIVWInverse variance weightedGRSGenetic risk score ER -